<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Büller, Harry R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">Rivaroxaban, a direct, specific, competitive factor Xa inhibitor that inhibits thrombin generation, is an effective treatment for venous thromboembolism. The Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism trial [EINSTEIN PE; Buller HR et al. N Engl J Med 2012] reported data that showed that rivaroxaban was noninferior to standard therapy but had a superior bleeding profile in patients with pulmonary embolism.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>